Gsk Quote - GSK

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1,320.00

Bid

1,322.50

Offer

1,323.00

Volume

13,999,772

1,302.50 Day's Range 1,323.50

1,282.50 52 Week Range 1,820.00

Market Cap

54.716B

Previous Close

1,322.00

Open

1,308.50

Last Trade

1313.5

(O)

Last Trade Time

Financial Volume

184,390,073p

VWAP

1,317.0934

Average Volume (3m)

8,557,049

Shares Outstanding

4,145,119,334

Dividend Yield

4.55%

PE Ratio

11.12

Earnings Per Share (EPS)

1.19

Revenue

30.33B

Net Profit

4.93B

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.gsk.com

Headquarters

London, Gbr

Founded

Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,322p. Over the last year, Gsk shares have traded in a share price range of 1,282.50p to 1,820.00p.

Gsk currently has 4,145,119,334 shares in issue. The market capitalisation of Gsk is £54.80 billion. Gsk has a price to earnings ratio (PE ratio) of 11.12.

GSK PLC Block Listing Application

GSK PLC 20 December 2024 GSK plc Block listing Application Application has been made to the Financial Conduct Authority and the London Stock Exchange plc for a total of 700,000...

GSK reports mixed findings from ovarian cancer phase III study

GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secon ...

GSK PLC Headline results from phase III FIRST trial

GSK PLC 20 December 2024 Issued: 20 December 2024, London UK GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer · ...

GSK receives three positive regulatory updates on cancer products

GSK PLC on Monday reported a triple dose of good news with positive regulatory updates on two leading cancer drugs. ...

GSK PLC Jemperli receives US FDA breakthrough designation

GSK PLC 16 December 2024 Issued: 16 December 2024, London UK Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer · ...

GSK PLC EMA grants PRIME Designation for GSK’227

GSK PLC 16 December 2024 Issued: 16 December 2024, London UK GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority Medicines (PRIME) Designation in relapsed...

GSK PLC Jemperli receives positive CHMP opinion

GSK PLC 16 December 2024 Issued: 16 December 2024, London UK Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to expand approval to all adult patients with primary...

GSK PLC Director/PDMR Shareholding

GSK PLC 12 December 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief...

GSK PLC Block Listing Application

GSK PLC 20 December 2024 GSK plc Block listing Application Application has been made to the Financial Conduct Authority and the London Stock Exchange plc for a total of 700,000...

GSK reports mixed findings from ovarian cancer phase III study

GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secon ...

GSK PLC Headline results from phase III FIRST trial

GSK PLC 20 December 2024 Issued: 20 December 2024, London UK GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer · ...

GSK receives three positive regulatory updates on cancer products

GSK PLC on Monday reported a triple dose of good news with positive regulatory updates on two leading cancer drugs. ...

GSK PLC Jemperli receives US FDA breakthrough designation

GSK PLC 16 December 2024 Issued: 16 December 2024, London UK Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer · ...

GSK PLC EMA grants PRIME Designation for GSK’227

GSK PLC 16 December 2024 Issued: 16 December 2024, London UK GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority Medicines (PRIME) Designation in relapsed...

GSK PLC Jemperli receives positive CHMP opinion

GSK PLC 16 December 2024 Issued: 16 December 2024, London UK Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to expand approval to all adult patients with primary...

GSK PLC Director/PDMR Shareholding

GSK PLC 12 December 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief...

IN BRIEF: GSK highlights positive Blenrep data from Dreamm-7 trial

based pharmaceuticals firm - Says Dreamm-7 trial shows sustained overall survival benefit for Blenrep, the brand name ...

GSK PLC Overall survival data presented for Blenrep

GSK PLC 09 December 2024 Issued: 9 December 2024, London UK Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first...

GSK's Nucala and Blenrep receive regulatory boost in US and China

GSK PLC on Monday received a double-dose of good news with its Nucala and Blenrep products receiving positive indicat ...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-13.5	-1.01237345332	1333.5	1345	1301	7164498	1327.32834751	DE
4	-5	-0.377358490566	1325	1398	1301	7692595	1343.87806727	DE
12	-205	-13.4426229508	1525	1559.5	1282.5	8557049	1396.80381692	DE
26	-299.5	-18.4933621488	1619.5	1678	1282.5	7803159	1481.9928947	DE
52	-125.8	-8.70106515424	1445.8	1820	1282.5	7852023	1560.95634199	DE
156	-265.8	-16.7612561483	1585.8	1824.4	1282.5	8592191	1526.54904742	DE
260	-489.6	-27.0557029178	1809.6	1857	1190.8	8762231	1506.7521004	DE

GSK - Frequently Asked Questions (FAQ)

What is the current Gsk share price?

The current share price of Gsk is 1,320.00p

How many Gsk shares are in issue?

Gsk has 4,145,119,334 shares in issue

What is the market cap of Gsk?

The market capitalisation of Gsk is GBP 54.8B

What is the 1 year trading range for Gsk share price?

Gsk has traded in the range of 1,282.50p to 1,820.00p during the past year

What is the PE ratio of Gsk?

The price to earnings ratio of Gsk is 11.12

What is the cash to sales ratio of Gsk?

The cash to sales ratio of Gsk is 1.81

What is the reporting currency for Gsk?

Gsk reports financial results in GBP

What is the latest annual turnover for Gsk?

The latest annual turnover of Gsk is GBP 30.33B

What is the latest annual profit for Gsk?

The latest annual profit of Gsk is GBP 4.93B

What is the registered address of Gsk?

The registered address for Gsk is 79 NEW OXFORD STREET, LONDON, WC1A 1DG

What is the Gsk website address?

The website address for Gsk is www.gsk.com

Which industry sector does Gsk operate in?

Gsk operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TIRTiger Royalties And Investments Plc	0.15p (50.00%)	3.41M
BAYBay Capital Plc	5.50p (19.57%)	209.68k
MASTMast Energy Developments Plc	0.19p (18.75%)	20.09M
MHNMenhaden Resource Efficiency Plc	148.50p (18.33%)	1M
ZENZenith Energy Ltd.	2.50p (16.28%)	3.93M
TRYBTribe Technology Plc	0.115p (-79.09%)	24.27M
NMTNeometals Ltd	2.75p (-35.29%)	49.4k
SNGSynairgen Plc	2.46p (-34.31%)	4.31M
TM1Technology Minerals Plc	0.185p (-26.00%)	174.03M
AYMAnglesey Mining Plc	0.70p (-17.65%)	2.99M
NTVONativo Resources Plc	0.002p (5.26%)	971.94M
TRPTower Resources Plc	0.035p (9.38%)	620.03M
LLOYLloyds Banking Group Plc	54.16p (-0.26%)	341.48M
ORCPOracle Power Plc	0.0255p (-1.92%)	192.93M
TM1Technology Minerals Plc	0.185p (-26.00%)	174.03M